FeesSafety
Pluang+

Aligos Therapeutics reports Q3 2026 results, advancing hepatitis B treatments with Phase 2 trial progress.

Company Fundamentals
06 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Aligos Therapeutics reports Q3 2026 results, advancing hepatitis B treatments with Phase 2 trial progress.

Aligos Therapeutics announced its Q3 2026 financial results and business updates, highlighting progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B. The study has completed enrollment with topline data expected in late Q3 2027. The company also reported ongoing Phase 1 trials of its antisense oligonucleotide ALG-170675 in China through partner Amoytop. Financially, Aligos posted a net loss of $21.9 million for Q3 2026, with cash reserves of $31.1 million expected to fund operations into early 2027. These developments bring Aligos closer to delivering new therapies for chronic HBV infection.

Aligos Therapeutics' recent business progress and Q3 2026 financial results provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 06, 2026 19:41 WIB: Of 150 priced health-sector US stocks tradable on Pluang, 52 rose and 90 fell today. Notable movers include Moderna, Inc. (MRNA) at USD 228.67 with a 1-day change of -5.30% and a typical hold time on Pluang of 58 days, Halozyme Therapeutics Inc. (HALO) at USD 117.01 down 4.84% with a typical hold time of 3 days, and Smith & Nephew plc (SNN) at USD 30.70 down 4.09% with a typical hold time of 123 days.

More News

Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...

Market News
Bullish
2 hours ago
Guggenheim raises JFrog price target to $125 after strong Q3 earnings and cloud revenue growth

Guggenheim raises JFrog price target to $125 after strong Q3 earnings and cloud revenue growth

Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...

Analyst Insights
Bullish
2 hours ago
Indonesia data center market to double to $4.05B by 2032, driven by cloud and AI infrastructure growth.

Indonesia data center market to double to $4.05B by 2032, driven by cloud and AI infrastructure growth.

The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...

Market News
Bullish
5 hours ago
Sky Prime Agent Grove’s Basin converts tokenized Treasury bills into $100K USDC to ease liquidity.

Sky Prime Agent Grove’s Basin converts tokenized Treasury bills into $100K USDC to ease liquidity.

Sky Prime Agent Grove’s Basin successfully converted 89,170 tokenized Treasury bills (JTRSY) into $100,000 in USDC stablecoins. This service is designed to help holders of tokenized Treasury bills access stablecoins while waiting for Treasury settlem...

Protocol Fundamentals
Neutral
5 hours ago
OpenAI pledges to pay power bills for its own data centers after election backlash, but excludes leased sites.

OpenAI pledges to pay power bills for its own data centers after election backlash, but excludes leased sites.

Following widespread voter rejection of local data center projects, OpenAI announced it will pay for electricity and grid infrastructure costs at data centers it owns and operates. However, the pledge excludes leased campuses and partner sites, leavi...

Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App